For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged. But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.

Trump Tariff and the Trade Turbulence – A Salil Kallianpur Blog

Impact of Trump’s 100% tariff on imported patented/innovative drugs...

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."